Table 2.

Clinical outcomes. Data are mean ± SD unless otherwise indicated.

Non-ULT treatment, n = 93Treatment with ULT, n = 65p
Baseline eGFR, ml/min/1.73 m244.94 ± 8.0944.70 ± 9.030.859*< 0.001**
eGFR after 1 year, ml/min/1.73 m241.51 ± 10.7645.29 ± 11.260.038*
p< 0.001†0.640†
eGFR after 2 yrs, ml/min/1.73 m239.42 ± 11.5746.67 ± 11.94< 0.001*
p< 0.001†0.130†
Last eGFR, ml/min/1.73 m237.57 ± 12.0143.51 ± 13.770.005*
p< 0.001†0.417†
eGFR change from baseline, ml/min/1.73 m2−7.37 ± 11.17−1.19 ± 12.070.001*
Renal disease progression, n (%)26 (27.90)8 (12.30)0.019*
Elapsed time from baseline to renal disease progression, weeks147.76 ± 107.94154 ± 125.400.892*
SUA (baseline), mg/dl8.00 ± 1.169.05 ± 1.91< 0.001*
SUA (last), mg/dl8.00 ± 1.396.05 ± 1.71< 0.001*
Actual SUA, mg/dl7.90 ± 0.877.02 ± 1.25< 0.001*
Systolic BP (baseline), mmHg138.16 ± 24.96129.54 ± 17.750.019*
Systolic BP (last), mmHg127.41 ± 15.98121.19 ± 17.670.024*
Diastolic BP (baseline), mmHg79.51 ± 17.0080.51 ± 13.790.699*
Diastolic BP (last), mmHg72.65 ± 11.0872.17 ± 10.490.791*
Controlled BP, n (%)36 (38.7)33 (51.5)0.141††

  • ↵* Independent 2-sample t test.

  • ↵** Repeated measures ANOVA.

  • ↵† Paired t test, comparison with baseline.

  • ↵†† Chi-squared test. ULT: urate lowering therapy; eGFR: estimated glomerular filtration rate; BP: blood pressure; SUA: serum uric acid.